McAdam LLC’s Maravai LifeSciences MRVI Stock Holding History

McAdam LLC’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,817	Closed	-$30.5K	–	384
2025 Q1	$30.5K	Buy	+13,817	New	+$54.6K	﹤0.01%	339

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

McAdam LLC's MRVI Position: Q2 2025 in Review

McAdam LLC sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 13,817 shares — an estimated $30.5K sold.

McAdam LLC first reported a position in MRVI in Q1 2025 and held it in 1 quarter. The position peaked at $30.5K in Q1 2025. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

McAdam LLC reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
McAdam LLC sold 13,817 Maravai LifeSciences shares in Q2 2025, an estimated $30.5K.
McAdam LLC first reported a position in Maravai LifeSciences in Q1 2025 and held it in 1 quarter.
McAdam LLC's Maravai LifeSciences position peaked at $30.5K in Q1 2025.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on McAdam LLC's 13F filing for Q2 2025, filed 15 Jul 2025.